12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HE2000: Began Phase I/II trial

Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif.
Product: HE2000
Business: Infectious diseases
Therapeutic category: Immune stimulation, Viral replication
Target: Host cell...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >